Navigation Links
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
Date:11/24/2008

Omrix's Biopharmaceutical Expertise Complements ETHICON's Industry-Leading Surgery Portfolio

NEW BRUNSWICK, N.J. and NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company and leading provider of suture, mesh, hemostats and other products for a wide range of surgical procedures.

The acquisition of Omrix would provide ETHICON with an opportunity to strengthen its presence in active, biologic-based hemostats and convergent products for various surgical applications. ETHICON currently has exclusive distribution rights in the U.S. and the European Union for EVITHROM(TM) Thrombin Topical (Human) and EVICEL(TM) Fibrin Sealant (Human), two active, biologic-based hemostats manufactured by Omrix. ETHICON and Omrix are also partnering on a Fibrin Pad product candidate, currently in Phase II clinical trials, as an adjunct to control mild to moderate soft tissue bleeding.

Under the terms of the agreement, Johnson & Johnson will commence a tender offer to purchase all outstanding shares of Omrix at $25.00 per share, which is expected to close by the end of December 2008. The tender offer is conditioned on the tender of a majority of the outstanding shares of Omrix's common stock on a fully diluted basis. The closing is conditioned on Israeli antitrust clearance and other customary closing condi
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
5. Johnson & Johnson Announces Changes to Accelerate Growth
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
8. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
9. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Migenix averts proxy contest; reaches agreement with DJohnson holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... 2014 Research and Markets ( ... "Glucose Sensors: the Next Generation" report ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of small-scale ... hope for a better future to millions of ... measure glucose levels accurately and reliably have the ...
(Date:12/12/2014)... Pittcon is pleased to announce the ... 2,000 technical presentations offered in symposia, oral sessions, ... covers a wide range of applications such as, ... environmental, food science, fuels/energy, genomics, lab management, materials ... Technical Program begins on Sunday, March 8 and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... to pursue a pivotal (Phase II/III) randomized ... in refractory,patients with head and neck cancers. ... results by the Company,s Board of Directors ...
... BOZEN, Italy, November 4 Health-Robotics today,announced ... strategic partnership with,Arabian Health Care Supply Corporation ... IV Solution provider within the Gulf,Cooperation Council ... cost-effectively automate the preparation of life-critical hazardous,and ...
... team up in specialty biologics development, TORONTO ... and,Therapure BioPharma Inc. have agreed to partner in ... for cancer treatments, with a goal of,advancing the ... a,marketing partner to add to its portfolio of ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 3Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 4Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... the challenges of increasing demands for food from a growing ... in the journal Science ., The goal of sustainable ... the article in the journal,s Policy Forum by lead authors ... of Oxford. They say this would minimise the pressure on ...
... Large-scale network organisation in the avian forebrain Birds ... years. So it,s hardly surprising that under a microscope, the ... a mammal. Nevertheless, birds have been shown to be remarkably ... puzzles. How is it that both kinds of brain are ...
... COLLEGE STATION Texas A&M University System scientists from ... science have developed a new medium for the cultivation ... of lactobacilli metabolism can help improve feed efficiency ... the researchers. "Lactobacilli are normal residents of the ...
Cached Biology News:The balancing act of producing more food sustainably 2The balancing act of producing more food sustainably 3Frontiers news briefs: July 4 2Frontiers news briefs: July 4 3Frontiers news briefs: July 4 4Frontiers news briefs: July 4 5Frontiers news briefs: July 4 6Newly developed medium may be useful for human health, biofuel production, more 2
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: